Literature DB >> 21382165

A novel and comprehensive mouse model of human non-alcoholic steatohepatitis with the full range of dysmetabolic and histological abnormalities induced by gold thioglucose and a high-fat diet.

Mitsunari Ogasawara1, Akira Hirose, Masafumi Ono, Kosuke Aritake, Yasuko Nozaki, Masaya Takahashi, Nobuto Okamoto, Shuji Sakamoto, Shinji Iwasaki, Taketoshi Asanuma, Taketoshi Taniguchi, Yoshihiro Urade, Saburo Onishi, Toshiji Saibara, Jude A Oben.   

Abstract

BACKGROUND: The search for effective treatments of non-alcoholic steatohepatitis (NASH), now the most common chronic liver disease in affluent countries, is hindered by a lack of animal models having the range of anthropometric and pathophysiological features as human NASH. AIMS: To examine if mice treated with gold thioglucose (GTG) - known to induce lesions in the ventromedial hypothalamus, leading to hyperphagia and obesity - and then fed a high-fat diet (HF) had a comprehensive histological and dysmetabolic phenotype resembling human NASH.
METHODS: C57BL/6 mice were injected intraperitoneally with GTG and then fed HF for 12 weeks (GTG+HF). The extent of abdominal adiposity was assayed by CT scanning. A glucose tolerance test and an insulin tolerance test were performed to evaluate insulin resistance (IR). Histological, molecular and biochemical analyses were also performed.
RESULTS: Gold thioglucose+HF induced dysmetabolism, with hyperphagia, obesity with increased abdominal adiposity, IR and consequent steatohepatitis, with hepatocyte ballooning, Mallory-Denk bodies, perivenular and pericellular fibrosis as seen in adult NASH, paralleled by an increased expression of the profibrogenic factors, transforming growth factor-β1 and TIMP-1. Plasma adiponectin and the expression of adiponectin receptor 1 and receptor 2 were decreased, while PPAR-γ and FAS were increased in the livers of GTG+HF mice. In addition, GTG+HF mice showed glucose intolerance and severe IR.
CONCLUSIONS: Treatment with GTG and HF diet induce, in mice, a comprehensive model of human NASH, with the full range of dysmetabolic and histological abnormalities.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21382165     DOI: 10.1111/j.1478-3231.2010.02443.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  10 in total

1.  Nutrigenomics of hepatic steatosis in a feline model: effect of monosodium glutamate, fructose, and Trans-fat feeding.

Authors:  Kate S Collison; Marya Z Zaidi; Soad M Saleh; Nadine J Makhoul; Angela Inglis; Joey Burrows; Joseph A Araujo; Futwan A Al-Mohanna
Journal:  Genes Nutr       Date:  2011-12-06       Impact factor: 5.523

2.  Time-dependent network analysis reveals molecular targets underlying the development of diet-induced obesity and non-alcoholic steatohepatitis.

Authors:  Hea-Young Oh; Su-Kyung Shin; Hyoung-Sam Heo; Ji-Sook Ahn; Eun-Young Kwon; Jung Han Yoon Park; Yun-Young Cho; Hae-Jin Park; Mi-Kyung Lee; Eun Jung Kim; Un-Ju Jung; Robin A McGregor; Cheol-Goo Hur; Myung-Sook Choi
Journal:  Genes Nutr       Date:  2012-11-13       Impact factor: 5.523

3.  Oral Administration of Compound Probiotics Ameliorates HFD-Induced Gut Microbe Dysbiosis and Chronic Metabolic Inflammation via the G Protein-Coupled Receptor 43 in Non-alcoholic Fatty Liver Disease Rats.

Authors:  Yinji Liang; Shu Liang; Yupei Zhang; Yuanjun Deng; Yifang He; Yanning Chen; Chan Liu; Chenli Lin; Qinhe Yang
Journal:  Probiotics Antimicrob Proteins       Date:  2019-03       Impact factor: 4.609

4.  A multi-mineral natural product inhibits liver tumor formation in C57BL/6 mice.

Authors:  Muhammad N Aslam; Ingrid Bergin; Madhav Naik; Anna Hampton; Ron Allen; Steven L Kunkel; Howard Rush; James Varani
Journal:  Biol Trace Elem Res       Date:  2012-01-06       Impact factor: 3.738

Review 5.  Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

Authors:  Yoshihisa Takahashi; Yurie Soejima; Toshio Fukusato
Journal:  World J Gastroenterol       Date:  2012-05-21       Impact factor: 5.742

6.  Metabolic improvement and liver regeneration by inhibiting CXXC5 function for non-alcoholic steatohepatitis treatment.

Authors:  Seol Hwa Seo; Eunhwan Kim; Minguen Yoon; Soung-Hoon Lee; Byung-Hyun Park; Kang-Yell Choi
Journal:  Exp Mol Med       Date:  2022-09-16       Impact factor: 12.153

7.  Bofutsushosan, a Japanese herbal (Kampo) medicine, attenuates progression of nonalcoholic steatohepatitis in mice.

Authors:  Masafumi Ono; Mitsunari Ogasawara; Akira Hirose; Sachiko Mogami; Nobuhiro Ootake; Kosuke Aritake; Takuma Higuchi; Nobuto Okamoto; Shuji Sakamoto; Masahiro Yamamoto; Yoshihiro Urade; Toshiji Saibara; Jude A Oben
Journal:  J Gastroenterol       Date:  2013-06-26       Impact factor: 7.527

8.  Preventive effects of total saponins of Panax japonicus on fatty liver fibrosis in mice.

Authors:  Ding Yuan; Tingting Xiang; Yuanxiu Huo; Chaoqi Liu; Ting Wang; Zhiyong Zhou; Yaoyan Dun; Haixia Zhao; Changcheng Zhang
Journal:  Arch Med Sci       Date:  2016-10-26       Impact factor: 3.318

Review 9.  Peculiarities of one-carbon metabolism in the strict carnivorous cat and the role in feline hepatic lipidosis.

Authors:  Adronie Verbrugghe; Marica Bakovic
Journal:  Nutrients       Date:  2013-07-19       Impact factor: 5.717

10.  Isoquercitrin activates the AMP-activated protein kinase (AMPK) signal pathway in rat H4IIE cells.

Authors:  Jingxin Zhou; Hisae Yoshitomi; Tonghua Liu; Boxin Zhou; Wen Sun; Lingling Qin; Xiangyu Guo; Liansha Huang; Lili Wu; Ming Gao
Journal:  BMC Complement Altern Med       Date:  2014-02-03       Impact factor: 3.659

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.